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ABSTRACT
Infections caused by carbapenem-resistant Enterobacterales (CRE) present an important therapeutic
problem, as there are limited number of effective therapeutic alternatives available. In this study,
phenotypic and genotypic methods were used to characterize carbapenemase-production and other
resistance-determinants (AmpC and ESBL-production, efflux pump-overexpression) in 50 isolates
(Klebsiella spp. n 5 35, Escherichia coli n5 12 and Enterobacter cloacae complex n5 3) collected at the
Albert Szent-Gy€orgyi Clinical Center (University of Szeged) between 2014 and 2017. Minimum
inhibitory concentrations of meropenem, sulfamethoxazole/trimethoprim, tigecycline, amikacin, mox-
ifloxacin, colistin and fosfomycin were also determined. 24% of isolates were AmpC-producers, while
30% carried blaCTX-M ESBL-genes. Carbapenemase-genes were detected in 18 (36%) of the tested iso-
lates: in 2 isolates blaNDM, in 6 isolates blaOXA-48-like and in 12 isolates, blaVIM was detected by PCR. The
species-distribution for isolates positive for carbapenemase-genes was the following: Klebsiella pneu-
moniae n 5 11, Klebsiella oxytoca n 5 1, E. coli n 5 5, E. cloacae complex n 5 1. Efflux pump-
overexpression based on the PAbN-screening agar was shown in n 5 3 of the tested strains. In nine
isolates (18%), carbapenemase and ESBL-genes were detected simultaneously. Highest levels of resis-
tance were noted for fosfomycin (74%) and moxifloxacin (70%), while all isolates were susceptible to
colistin. Among applied phenotypic tests in this study the modified carbapenem inactivation method
(mCIM) proved to be the most accurate one compared to that of PCR results.
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INTRODUCTION
Carbapenems, namely imipenem (introduced in 1985), meropenem (1996), ertapenem
(2003) and doripenem (2007) are b-lactam-antibiotics with some of the broadest spectrum
and bactericidal activity; they are effective in the therapy of infections caused by aerobic and
anaerobic Gram-positive and Gram-negative pathogens (including non-fermenters, with the
exception of ertapenem) [1, 2]. Initially, carbapenems were exclusively used as monotherapy
for life-threatening infections, however, after the rise and global spread of extended-spectrum
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b-lactamase (ESBL)-producing Enterobacterales, it has
become an established clinical practice to use these agents in
first-line empirical therapy [2, 3]. Nevertheless, the extensive
use of these agents resulted in the emergence of carbape-
nem-resistant Gram-negative strains [4]. From a clinical
standpoint, carbapenem-resistant Gram-negative bacilli
(CRGNB) present an important therapeutic problem, as
there are limited number of safe and effective therapeutic
alternatives available [5, 6]. Carbapenem resistance may
develop through a variety of cellular mechanisms: alteration
in membrane permeability and porin loss (e.g., ΔOmpK in
Klebsiella pneumoniae), overexpression of efflux pumps,
changes in penicillin-binding proteins; however, the most
prevalent mechanism of resistance is through the production
of specific b-lactamases called carbapenemases, capable of
hydrolyzing these antibacterial drugs [4, 7–10]. The differ-
entiation of carbapenemase-producing carbapenem resistant
Enterobacterales (CP-CRE; with Klebsiella spp. represented
in highest numbers) from non-carbapenemase producing
carbapenem resistant Enterobacterales (CRE) is of utmost
importance, as the resistance-determinants of CP-CREs are
readily transferable on plasmids or integrons, having a role
in nosocomial outbreaks and global dissemination [11, 12].
Based on sequence similarity, carbapenemases are classified
into Ambler Class A e.g. KPC, SME, NMC-A, IMI, PER,
GES, SFO, SFC and IBC), Class D (e.g. OXA-23 group,
OXA-48-group) and Class B (e.g. VIM, GIM, SIM, NDM,
IMP, IND, AIM, DIM and SPM) enzymes; while the first
two groups consist of serine-b-lactamases, the members of
the latter group are exclusively metallo-b-lactamases [13,
14]. Different carbapenemases have varying epidemiological
significance around the world and in Europe, based on their
origins and dissemination levels: ST258 blaKPCs most likely
have spread to Europe from the United States, while ST512
blaKPCs are suggested to have spread to Europe from Israel
[15]; blaVIM-1 emerged in Greece and blaOXA-48 emerged in
Turkey and spread to Europe through the Mediterranean
[16]. In Hungary, the first published case of carbapenemase-
production in an Enterobacterales clinical isolate was re-
ported in a KPC-2 and SHV-12-producing K. pneumoniae;
the isolate originated from a patient, who has been previ-
ously hospitalized in Greece and caused a local outbreak in
the northeastern region of the country [16, 17].
Various laboratory methods are available for the detection
of CP-CRE strains, although the methods-of-choice are highly
dependent on the epidemiological situation and the economic
possibilities of the given healthcare settings [18]. Molecular
methods, such as polymerase chain reaction (PCR) and
whole-genome sequencing (WGS) are considered as the gold
standard for detection of carbapenemase genes, nevertheless,
their high laboratory costs make them unsuitable for many
smaller, low-resource laboratories [19]. In addition, molecular
methods are only capable of detecting already known resis-
tance-determinants. Thus, carbapenemase-detection is usually
carried out as a step-wise process: if carbapenemase-produc-
tion is suspected based on the results of antimicrobial sus-
ceptibility testing, phenotypic screening (e.g., chromogenic
media) or confirmatory tests (detection of diffusible
carbapenemases, carbapenemase-inhibitor assays, assessment
of carbapenem hydrolysis activity by measuring pH-change
or spectrophotometry), followed by molecular methods, if
available [18–21]. Additionally, the use of lateral flow assays,
microarray technology and matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry for carbapene-
mase-detection has also been described [22, 23].
In the suspicion of CP-CRE arises, rapid screening and
verification is essential, both to ensure appropriate therapy
to the affected patients and to allow for infection control
measures to take place [16, 18]. Knowledge on the local
epidemiology of each healthcare institution regarding car-
bapenemase-producing strains is of utmost importance, as
this may aid the selection of the ideal methodology for their
screening [16, 18]. The aim of our study was the charac-
terization of Enterobacterales strains suspected of carbape-
nemase-production in a low-prevalence setting in Hungary,
through the use of various phenotypic and genotypic
methods.
MATERIALS AND METHODS
Bacterial strains, identification, inclusion criteria
Fifty (n 5 50) Enterobacterales strains, isolated from clinical
samples between 2014 and 2017 at the Institute of Clinical
Microbiology (Albert Szent-Gy€orgyi Clinical Center, Szeged,
Hungary) were included in this study. The identification of
these isolates was carried out using MALDI-TOF MS. Mass
spectrometry was performed by Microflex LT MALDI Biotyper
(Bruker Daltonics, Bremen, Germany) instrument, using the
MALDI Biotyper RTC 3.1 software and the MALDI Biotyper
Library 3.1 for the spectrum analysis (Bruker Daltonics, Ger-
many). The sample preparation, methodology, and technical
specification of the MALDI-TOF MS measurements were
described elsewhere [24]. Inclusion of these strains was based
on the screening criteria recommended by the ESCMID/
EUCAST guidelines (meropenem disk diameter <28 mm) [25].
Minimum inhibitory concentrations (MICs) of
meropenem and ancillary antibiotics
MICs of meropenem (MER), sulfamethoxazole/trimetho-
prim (SXT), tigecycline (TIG), amikacin (AMK) and moxi-
floxacin (MOX) were determined by E-tests (Liofilchem,
Roseto degli Abruzzi, Italy) on Mueller-Hinton agar plates
(Oxoid, Basingstoke, UK). MIC determination for colistin
(COL) was carried out using the broth microdilution
method in cation-adjusted Mueller-Hinton broth (MERLIN
Diagnostika, Berlin, Germany) [24, 26]. MIC determination
for fosfomycin (FOS) was carried out using the agar dilution
method, on Mueller-Hinton agar plates supplemented with
25 mg/L glucose-6-phosphate and varying concentrations of
FOS. The interpretation of the results was based on
EUCAST Clinical Breakpoints v.9 (http://www.eucast.org).
In case of isolates other than E. coli, epidemiological cut-off
values were used for tigecycline (MIC≤1 mg/L as suscepti-
ble, MIC>1 mg/L as resistant) [26].
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Phenotypic detection of AmpC-b-lactamases and
ESBL-enzymes
The strains included in the study were screened for AmpC-b-
lactamase-production by cefoxitin disks (30 mg; Oxoid,
Basingstoke, UK) [27]. Phenotypic verification of AmpC-b-
lactamase and ESBL-production was carried out using AmpC-
ESBL Detection Set (MAST Diagnostica, Reinfeld, Germany)
and VITEK 2 Compact ID/AST (bioMerieux, Marcy-l’Etoile,
France), according to the manufacturer’s instructions.
Phenotypic screening and verification of
carbapenemase-production
For phenotypic screening of carbapenemase-production, the
chromID CARBA SMART agar (CARB/OXA; bioMerieux,
Marcy-l’Etoile, France) was used; this medium consists of a
nutrient base, combining different peptones, three chromogenic
substrates enabling the detection of specific metabolic enzymes
for E. coli, Klebsiella spp., Enterobacter spp., Serratia spp. and
Citrobacter spp., in addition to a proprietary mixture of antibi-
otics, favoring the selective growth of carbapenemase-producers
[28]. The phenotypic verification of carbapenemase-production
was carried out using themodified cloverleaf (orHodge) test and
the modified carbapenem inactivation method (mCIM), as
previously described [29, 30]. In both assays, meropenem disks
(10 mg; Oxoid, Basingstoke, UK) were utilized and E. coliATCC
25922 was used as an indicator organism.
Phenotypic detection of efflux pump-overexpression
Theeffectsofphenylalanine-arginineb-naphthylamide (PAbN),
on theMICsofmeropenemweredetectedusing the agar dilution
method described previously [27]. During the experiments, the
concentration of PAbNwas 40mg/mL in the agar base. Two-fold
decrease in theMICs of meropenem in the presence of PAbN (a
compound with well-known efflux-pump inhibitory activity
[30]), compared to the MIC values without the inhibitor was
considered as positivity for efflux pump overexpression.
Molecular detection of ESBL and carbapenem-
resistance genes
Molecular detection of resistance genes encoding for ESBLs
and carbapenemases was carried by multiplex PCR with
previously described protocols [31–33].
Statistical analyses
Based on the data provided during our experiments, sensi-
tivity, specificity, positive and negative predictive values (SN,
SP, PPV and NPV, respectively) were calculated for each
test, as described previously [34].
RESULTS
Sample types and species composition of the isolates
During the 4-year study period, 50 Enterobacterales isolates
with meropenem disk diameters under 28 mm were
detected: the majority (n 5 35) of these isolates were Kleb-
siella spp. (K. pneumoniae: n 5 34, Klebsiella oxytoca: n 5
1), while E. coli (n 5 12) and E. cloacae complex (n 5 3)
were also suspected for carbapenemase-production in lower
numbers. These isolates originated from the following
samples: urine: n 5 19 (midstream urine: n 5 14, catheter-
specimen urine: n 5 5), feces: n 5 14, tracheal aspirate: n 5
7, abscess: n 5 4, aerobic wound culture and bile: n 5 3,
respectively.
MICs of tested antibiotics
The MICs of tested antibiotics, including MIC50, MIC90
values, MIC ranges and the percentage of resistant isolates
are presented in Table 1. The highest levels of resistance
were observed for FOS (n 5 37, 74%), followed by MOX (n
5 35, 70%), while non-susceptibility of the isolates for SXT
and AMK were around 50%. All tested isolates were sus-
ceptible to colistin, with MIC values ranging between 0.25
and 1 mg/L. Based on EUCAST breakpoints, n 5 14 (28%)
of isolates showed MICs above the resistance breakpoint (8
mg/L) for meropenem, with MICs ranging between 0.25 and
32 mg/L. Highest MICs were observed for the blaNDM and
several blaVIM-expressing strains, while in n 5 4 (8%) of
cases, strains carrying blaOXA48-like enzymes showed MICs in
low-to-moderate range (0.5–1 mg/L) (Table 1.).
Phenotypic and genotypic detection of resistance-
determinants
Based on the cefoxitin screening disk, 14 out of 50 isolates
(28%) were suspected of AmpC b-lactamase-production,
while based on the AmpC-ESBL Detection Set, n5 12 (24%)
of these isolates were phenotypically verified as AmpC-
producers. The AmpC-ESBL Detection Set showed ESBL-
production in n 5 15 (30%) isolates; in line with phenotypic
results, blaCTX-M-type ESBL-genes were detected in all of
these isolates. In n 5 6 (12%) of isolates, AmpC and ESBL
co-production was verified, both by phenotypic and geno-
typic methods.
Using the modified cloverleaf test, 20 isolates showed
positive results for carbapenemase-production, while this
number was n 5 19 for the chromID CARBA SMART agar
and n 5 18 for the mCIM assay. Carbapenemase-genes were
Table 1. MIC values of meropenem and ancillary antibiotics on the
tested bacterial strains
Resistant
strains (n,
%)
MIC
range
(mg/L)
MIC50
(mg/L)
MIC90
(mg/L)
Meropenem 14 (30%) 0.25–32 8 16
Amikacin 24 (48%) 1–16 4 16
Colistin 0 (0%) 0.25–1 0.5 1
Fosfomycin 37 (74%) 1–64 16 64
Moxifloxacin 35 (70%) 0.064–1 0.25 1
Sulfamethoxazole/
trimethoprim
24 (48%) 0.064–16 2 8
Tigecycline 16 (32%) 0.064–1 0.25 1
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detected by PCR in n 5 18 (36%) of the tested isolates: in 2
strains blaNDM, in 6 strains were blaOXA-48-like and in 12
blaVIM was detected. In nine isolates (18%), carbapenemase
and ESBL-genes were detected simultaneously (blaVIM and
blaCTX-M co-detection in n 5 7 cases, blaOXA-48-like and
blaCTX-M co-detection in n 5 2 cases). The species-distri-
bution for isolates positive for carbapenemase-genes was the
following: K. pneumoniae n 5 11, K. oxytoca n 5 1, E. coli n
5 5, E. cloacae complex n 5 1. No ESBL or carbapenemase-
encoding genes or phenotypic AmpC-production were
detected in n 5 5 (10%) of isolates. Efflux pump-over-
expression based on the PAbN-screening agar was shown in
3 (6%) of the tested strains only: one isolate was ESBL-
positive, one was an AmpC-producer, while in one isolate,
no other resistance determinant could be detected.
Based on the comparative analysis of phenotypic and
genotypic carbapenemase detection methods (considering
molecular methods as the gold standard), three isolates
presented false-positive (17/20 were true positives) and one
presented as false-negative (29/30 were true negatives), while
the chromogenic screening agar showed once false-positive
(18/19 were true positives). False positivity was noted in case
of an AmpC-producer (E. coli), an AmpC-ESBL co-producer
(E. cloacae complex) and an AmpC-efflux pump over-
expresser (K. pneumoniae); in contrast, the strain presenting
as false-negative in both methods was a blaOXA-48-like-pro-
ducer. The mCIM method was completely in line with the
results of genotypic testing (zero false positives or false
negatives). Determination of the predictive power of the
individual screening and verification tests is presented in
Table 2.
DISCUSSION
Members of the Enterobacterales order are common causes of
both community-acquired and nosocomial infections, including
bloodstream-infections, lower respiratory tract infections and
urinary tract infections [35].Carbapenemshavebecomeessential
components of therapy in infections caused by extended-spec-
trum cephalosporin resistant strains, especially for vulnerable
patientgroups, suchas children,pregnantwomenand the elderly
[1–4, 36]. Although intrinsic resistance to carbapenems has been
previously described in Stenotrophomonas maltophilia
(conferred by the metallo-b-lactamase L1), acquired
carbapenem-resistance (through mutational events or via hori-
zontal gene transfer)hasemergedasasignificantclinicalproblem
in the last 15–20 years [37, 38]. The spread of carbapenem-
resistant strains in nosocomial settings, where MDR Gram-
negative bacteria are already endemic, is especially daunting [39].
Thesepathogensmayacquireresistancedeterminants,conferring
resistance for multiple antibiotic classes, leading to virtually
untreatable infections [40]. CP-CRE species have now been re-
portedworldwide; carbapenemaseshavemainlybeen found inK.
pneumoniae, and to a much lesser extent in E. coli and other
members of theEnterobacterales order [41]. Basedon estimation
of the Centers for Disease Control and Prevention (CDC), car-
bapenem-resistant Enterobacterales species may be causative
agentsinupto9,000infectionand600excessdeathsperyearinthe
US [42]. Similarly, the Burden of Antimicrobial Resistance
Collaborative Group estimated that in Europe, around 16,000
infections and 2000 attributable deaths occurred in 2015 due to
carbapenem-resistant K. pneumoniae [43]. The distribution of
carbapenemase-producing isolates worldwide has been recently
summarizedbytheCenter forDiseaseDynamics,Economicsand
Policy database: according to this database, blaOXA-48-like is
endemic in Africa, blaOXA-48-like, blaNDM, blaKPC and blaIMP in
Asia,blaKPCintheAmericanContinentandblaOXA-48-like,blaVIM,
blaKPC and blaIMP inEurope [44]. Based on thedata of theECDC
Surveillance on Antimicrobial Resistance in 2017 and 2018,
Greece had the highest levels of carbapenem-resistant isolates
(64.7 and 63.9% forK. pneumoniae and 1.6 and 2.0% for E. coli),
followed by Italy (26.8 and 29.7% for K. pneumoniae) and
Romania (22.5 and 29.5% for K. pneumoniae) [45]; this is not
surprising, as Greece has been considered the epicenter of CP-
CRE strains on the continent, where the spread of these strains
usually showed a south-to-north gradient [37, 38]. In Hungary,
theratioofcarbapenem-resistantE.colistrainswas<0.1%forboth
years,while forK.pneumoniae, thepercentageof relevant isolates
was still very low (0.2 and 0.3%, respectively) [23, 42].
The costs, turnaround-time, accuracy, the information
provided by these screening and phenotypic tests and the ex-
pected output (clinical, local or regional epidemiology or na-
tional/international surveillance) all need to be taken into
consideration when opting for a carbapenemase-detection
strategy [46]. While some test may be suitable for local
microbiology laboratories for rapid therapeutic decisions,
others will only be available to reference laboratories. The
phenotypic detection of carbapenemases is hindered by their
diversity, the pronounced differences in hydrolytic ability and
their frequent co-occurrence with other resistance mechanisms
influencing b-lactam resistance [47, 48]. For example, in strains
with ESBLs or AmpC-hyperproduction, coupled with porin
loss and/or efflux pump-overexpression, a similar phenotype
may be observed to carbapenemase-production in phenotypic
tests [47, 48]. On the other hand, some carbapenemase-en-
zymes do not confer high MICs to the isolates, therefore there
is a risk that they will be missed by disk diffusion/gradient tests
[49]. In addition, the local epidemiology of carbapenemases
also influences the phenotypic tests employed, based on the
sensitivity of these tests for the specific enzymes [16, 18]. The
advantage of inhibitor tests is that they may be used to
distinguish between different types (i.e. serine or metallo-b-
Table 2. Calculated predictive power of the individual screening
and verification tests employed the study
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Modified cloverleaf
(Hogde) test
94.7 91.4 85.7 96.9
chromID CARBA
SMART
100 96.9 94.7 100
Modified carbapenem
inactivation method
(mCIM)
100 100 100 100
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lactamases) or enzymes [47, 48]. The poor sensitivity and
specificity of the modified cloverleaf (Hodge) test has been
documented previously: false-positive results are common in
other b-lactamase (ESBL or AmpC) producers, with or without
porin mutations or efflux pumps, while some types of carba-
penemases (blaOXA-48-like and blaNDM-types, although the
introduction of Zn2þ to the culture media results in increased
sensitivity for the latter type) have shown false-negative results
[49]. Several modifications and adjustments have been pub-
lished with the aim of improving the detection parameters of
this assay [50]. The advantage of screening media (e.g., chro-
mID CARBA SMART utilized in this study) is that they are
ready-to-use, assistant-friendly and ease of interpretation and
sensitivity/specificity of this method has been demonstrated to
be around 96–100/97–100% in several studies [26, 51];
nevertheless, the verification of culture results with additional
phenotypic tests is recommended. The modified carbapenem-
inactivation method (mCIM) is easy-to-perform and the
panels can be prepared in-house; this assay has also demon-
strated sensitivities/specificities ≥98% in many publications
[27, 52]. The use of the CarbaNP confirmatory test (and the
numerous iterations of this method) is becoming more and
more widespread: the method is based on the direct detection
of carbapenem hydrolysis, and similarly to the mCIM test,
both commercial and in-house panels are available to use [53].
Nonetheless, molecular methods (predominantly single or
multiplex PCR-based, with results in 2–6 hours) remain the
reference for identification and differentiation of carbapene-
mases and this may be followed by sequencing, if available [18,
54]. Their cost and the need for trained technicians however,
are significant drawbacks.
While therehasbeensomedevelopments in the introduction
of new b-lactam/non-boronic or boron-based b-lactamase-in-
hibitorcombinations (e.g., ceftolozane/tazobactam,ceftazidime/
avibactam, meropenem/vaborbactam) in therapy for Class A
carbapenemases,wecurrentlydonotpossessadequateb-lactam-
therapy for metallo-b-lactamase-producing (Class B) strains
[55]; these Zn2þ-dependent enzymes are inhibited by metal
chelators, such as EDTA or dipicolinic acid, but no clinically-
relevant metallo-b-lactamase-inhibitor has been identified thus
far [56]. An additional therapeutic concern is the possibility of
strains possessing more than one type of carbapenemase, elim-
inating b-lactams as potential therapeutic options [56]. Carba-
penemases inEnterobacteralesaremostlyplasmid-encodedand
are often associated with resistance-determinants to other an-
tibiotics, especially for fluoroquinolones and aminoglycosides
[57]. Colistin is nephrotoxic and neurotoxic polycationic pep-
tide, which is usually considered as a last-resort agent in
MDR Gram-negative infections [58]; in our study, all of the
tested isolates were susceptible. Nonetheless, the increasing
frequency of reports on colistin-resistance in Enterobacterales
and non-fermenters is a serious concern; in the EuSCAPE
Survey (European survey of carbapenemase-producing Enter-
obacteriaceae) 28.3%ofCRE isolateswere also colistin-resistant
[59]. TIG resistance was observed in 32% of isolates; this agent
has been introduced with great promise in the therapy ofMDR
Gram-negative infections, however, the black-box warning is-
sued by the FDA (due to increased overall mortality in TIG-
treated patients) and low tissue penetration and serum-levels, it
didnot liveupto theexpectations.Theuseof intravenousFOSin
the therapy of MDR Gram-negative bacteria has been exten-
sivelyreportedasapromisingalternative [60];nevertheless,74%
ofour isolates testedwere resistant to thisantibiotic. InaTurkish
study, the susceptibilities of CP-CRE isolates were assessed and
the authors reported 76.2% of isolates as COL-resistant and
67.4% as FOS-resistant [26]. On the other hand, the literature is
scarce on the relevance of SXT-therapy for CP-CRE infections:
in our study, 48% of isolates were still susceptible to SXT; in the
CRACKLE-1 cohort study in the US, 29% of pathogens in CP-
CRE infections were susceptible to SXT and one-third of these
affected patients were successfully treatedwith the drug [61]. In
contrast, in a survey involving n5 181 CP-CRE isolates, Baran
et al. showed that SXT-resistance in E. coli and K. pneumoniae
was61and55%,respectively[62].CP-CREisolateshaveveryfew
or no therapeutic options (depending on resistance rates to
ancillary antibiotics) available. Thus, their optimal monitoring
and rapid detection for therapeutic, infection control and
epidemiological purposes is needed. The findings of our study
indicate that out of the 50 suspected isolates, presence of car-
bapenemase-genes verified in 18 strains, and the phenotypic
methods utilized (especially the chromogenic media for
screeningandmCIMforverification)were appropriate touse in
our settings. Nevertheless, every laboratory and/or healthcare
institutionneeds topre-test various testingmethodsandconsult
thenational reference laboratory to select foradequatedetection
methods for carbapenemase-producers.
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